These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8518326)

  • 1. Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.
    Jedrychowski M; Feifel N; Bieck PR; Schmidt EK
    J Pharm Biomed Anal; 1993 Mar; 11(3):251-5. PubMed ID: 8518326
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
    Feifel N; Kucher K; Fuchs L; Jedrychowski M; Schmidt E; Antonin KH; Bieck PR; Gleiter CH
    Eur J Clin Pharmacol; 1993; 45(3):265-9. PubMed ID: 8276052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.
    Schneider W; Keller B; Degen PH
    J Chromatogr; 1989 Mar; 488(1):275-82. PubMed ID: 2715286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P; Dahl M; Andersson K; Bertilsson L
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
    Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
    Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
    Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
    Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
    Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
    Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients.
    Bendriss A; Bechtel Y; Paintaud G; Bendriss EK; Joanne C; Bresson-Hadni S; Magnette J; Becker MC; Gillet M; Mantion G
    Ther Drug Monit; 1995 Apr; 17(2):113-9. PubMed ID: 7624897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
    Kronbach T
    Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
    [No Abstract]   [Full Text] [Related]  

  • 16. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
    Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
    Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
    Chapman PH; Rawlins MD; Shuster S; Idle JR; Ritchie JC; Smith RL
    Eur J Clin Pharmacol; 1981; 21(3):257-8. PubMed ID: 6895622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.